Edition:
United Kingdom

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

10.02USD
14 Dec 2018
Change (% chg)

$-0.50 (-4.75%)
Prev Close
$10.52
Open
$10.46
Day's High
$10.69
Day's Low
$9.97
Volume
91,835
Avg. Vol
116,658
52-wk High
$31.91
52-wk Low
$9.97

Latest Key Developments (Source: Significant Developments)

Voyager Therapeutics Q2 GAAP Loss Per Share $0.80
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.Q2 GAAP LOSS PER SHARE $0.80.Q2 EARNINGS PER SHARE VIEW $-0.67 -- THOMSON REUTERS I/B/E/S.COLLABORATION REVENUES OF $2.6 MILLION FOR Q2 OF 2018.  Full Article

Voyager Receives FDA Guidance On Development Path For VY-AADC For Parkinson’s Disease
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS RECEIVES FDA GUIDANCE ON DEVELOPMENT PATH FOR VY-AADC FOR PARKINSON’S DISEASE AND PROVIDES CLINICAL UPDATE.VOYAGER THERAPEUTICS INC - CONTINUES TO PLAN TO SUBMIT A BLA FOR VY-AADC BASED ON ITS PIVOTAL PROGRAM AND TYPE C MEETING FEEDBACK.VOYAGER THERAPEUTICS INC - POSITIVE INTERIM RESULTS WITH VY-AADC FROM PHASE 1 POSTERIOR TRAJECTORY TRIAL.VOYAGER THERAPEUTICS - BELIEVES WRITTEN RESPONSES FROM FDA TO QUESTIONS WERE INFORMATIVE & CAN BE ADDRESSED TO SUPPORT SUBMISSION OF A BLA FOR REVIEW.  Full Article

Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease
Friday, 9 Mar 2018 

March 9 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES LONGER-TERM DATA FROM ONGOING PHASE 1B TRIAL OF VY-AADC FOR ADVANCED PARKINSON’S DISEASE.VOYAGER THERAPEUTICS - ‍PIVOTAL PHASE 2-3 PROGRAM REMAINS ON TRACK TO DOSE FIRST PATIENT MID-2018​.  Full Article

Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE.VOYAGER THERAPEUTICS INC - CONTINUE TO PLAN TO DOSE FIRST PATIENT IN PIVOTAL PHASE 2-3 PROGRAM FOR ADVANCED PARKINSON'S DISEASE DURING Q2.  Full Article

BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - BB Biotech Ag::BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING‍​.  Full Article

Voyager Therapeutics prices public offering of 4.50 mln common shares at $12/shr
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces pricing of public offering of common stock.Says public offering of 4.50 million common shares priced at $12.00per share.  Full Article

Voyager Therapeutics announces proposed offering of common stock
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces proposed offering of common stock.Voyager Therapeutics Inc - ‍commencing an underwritten public offering of $75 million of shares of its common stock​.  Full Article

Voyager Therapeutics reports Q3 GAAP loss per share $0.89
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics Inc reports third quarter 2017 financial results and corporate highlights.Q3 GAAP loss per share $0.89.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Voyager Therapeutics Inc - ‍total cash, cash equivalents, and marketable debt securities as of september 30, 2017 were $125.6 million​.Voyager Therapeutics Inc - ‍continues to expect to end 2017 with total cash, cash equivalents, and marketable debt securities of about $90 million to $100 million​.Voyager Therapeutics Inc - ‍existing cash, cash equivalents, marketable debt securities will be sufficient to fund operating expenses and capex requirements into 2019​.  Full Article

Voyager Therapeutics announces lead clinical candidate selection
Monday, 13 Feb 2017 

Voyager Therapeutics Inc : Voyager Therapeutics announces lead clinical candidate selection for monogenic form of amyotrophic lateral sclerosis (ALS) .Voyager Therapeutics-preclinical studies now underway to support filing of an investigational new drug application for VY-SOD101 during Q4 of 2017.  Full Article